Actinium Pharmaceuticals, Inc (ATNM) is a publicly traded Healthcare sector company. As of May 21, 2026, ATNM trades at $1.20 with a market cap of $36.71M and a P/E ratio of -1.55. ATNM moved +1.30% today. Year to date, ATNM is -19.31%; over the trailing twelve months it is -36.07%. Its 52-week range spans $0.95 to $2.41. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces ATNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ATNM financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ATNM recently traded at $1.20. Market cap is $36.71M. P/E ratio is -1.55. Revenue is $90.00K.
| Metric | Value |
|---|---|
| Price | $1.20 |
| Market Cap | $36.71M |
| P/E Ratio | -1.55 |
| EPS | $-0.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.41 |
| 52-Week Low | $0.95 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $90.00K |
| Net Income | $-23.47M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $90.00K | $-33.89M | $-1.09 |
| 2024 | $0 | $-38.24M | $-1.27 |
| 2023 | $81.00K | $-48.82M | $-1.83 |
| 2022 | $1.03M | $-33.02M | $-1.37 |
3 analysts cover ATNM: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.